Investing.com - Biomarin Pharma reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $-0.2 on revenue of $408.7M. Analysts polled by Investing.com EPS of $-0.2427 on revenue of $435.89M.
Biomarin Pharma 's are down 18.21% and is trading at $71.50 , still down 22.51% from its 52 week high of $92.55 set on Thursday, December 17, 2020.
Biomarin Pharma shares lost 0.31% to trade at $71.50 in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on Tuesday, October 19, 2021, who reported EPS of $2.6 on revenue of $23.34B, EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on revenue of $9.33B, for EPS of $4.68 on revenue of $8.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar